“Rising Adoption of Immunotherapy and Personalized Medicine in Ocular Oncology”
- One prominent trend in the treatment of eye melanoma is the increasing adoption of immunotherapy and personalized medicine, particularly through the use of immune checkpoint inhibitors and gene-targeted therapies
- These advanced treatment approaches are tailored to the patient’s specific tumor genetics and immune profile, offering enhanced efficacy and fewer side effects compared to traditional therapies
- For instance, immune checkpoint inhibitors such as pembrolizumab (anti-PD-1) and ipilimumab (anti-CTLA-4) have shown promising results in treating metastatic uveal melanoma, a rare but aggressive form of eye cancer. Their use is expanding in oncology protocols globally.
- As precision oncology evolves, combining genomic profiling with targeted therapies is transforming ocular cancer care, improving survival rates and boosting demand for innovative drug solutions
